Zydus Lifesciences · NSE: ZYDUSLIFE · BSE: 532321
Q1 FY27 results · Apr–Jun 2026
Zydus Lifesciences reported revenue from operations of ₹8,017.00 crore (up 22.0% from Q1 FY26) and net profit of ₹990.20 crore (down 34.9% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 8,017.00 | 6,573.70 | +22.0% | 7,587.00 | +5.7% |
| Other income | 106.10 | 154.90 | −31.5% | 134.20 | −20.9% |
| Total income | 8,123.10 | 6,728.60 | +20.7% | 7,721.20 | +5.2% |
| Profit before share of associates & JVs and tax | 1,306.60 | 1,920.60 | −32.0% | 1,659.70 | −21.3% |
| Share of profit/(loss) of associates & JVs | 37.80 | 34.40 | (0.30) | ||
| Net profit for the period | 990.20 | 1,521.00 | −34.9% | 1,341.00 | −26.2% |
| Attributable to shareholders of the company | 939.80 | 1,466.80 | −35.9% | 1,272.50 | −26.1% |
| EPS, basic (₹) | 9.35 | 14.58 | −35.9% | 12.65 | −26.1% |
| Net margin (%) | 12.4 | 23.1 | 17.7 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,872.20 | 2,588.30 | +11.0% | 3,740.90 | −23.2% |
| Other income | 123.70 | 157.10 | −21.3% | 495.10 | −75.0% |
| Total income | 2,995.90 | 2,745.40 | +9.1% | 4,236.00 | −29.3% |
| Profit before tax | 455.70 | 474.90 | −4.0% | 2,111.00 | −78.4% |
| Net profit for the period | 339.60 | 384.70 | −11.7% | 1,722.00 | −80.3% |
| EPS, basic (₹) | 3.38 | 3.82 | −11.5% | 17.11 | −80.2% |
| Net margin (%) | 11.8 | 14.9 | 46.0 |
Consolidated
- Filed with BSE
- 11 Aug 2026, 19:24 IST
- Board meeting
- 11 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Aug 2026, 19:24 IST
- Board meeting
- 11 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE